Do analysts rate FOXX or QCLS?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Foxx Development 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Mymd Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts prefer EBON or QCLS?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ebang International 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Mymd Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation & earnings, EBON or QCLS?

Mymd Pharmaceuticals has lower revenue, but higher earnings than Ebang International. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Ebang International $6.54M 2.23 -$14.09M N/A N/A Mymd Pharmaceuticals N/A N/A -$11.63M -$3.48 N/A

Is EBON or QCLS more profitable?

Ebang International's return on equity of 0.00% beat Mymd Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Ebang International N/A N/A N/A Mymd Pharmaceuticals N/A -91.64% -47.48%

Do analysts prefer QCLS or AIMD?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mymd Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Ainos 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is QCLS or AIMD more profitable?

Mymd Pharmaceuticals has a net margin of 0.00% compared to Ainos' net margin of -11,912.10%. Mymd Pharmaceuticals' return on equity of -91.64% beat Ainos' return on equity. Company Net Margins Return on Equity Return on Assets Mymd Pharmaceuticals N/A -91.64% -47.48% Ainos -11,912.10% -217.50% -67.87%

Do analysts recommend QCLS or BOXL?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mymd Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Boxlight 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts recommend TNFA or QCLS?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TNF Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Mymd Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings & valuation, TNFA or QCLS?

Mymd Pharmaceuticals is trading at a lower price-to-earnings ratio than TNF Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio TNF Pharmaceuticals N/A N/A -$23.36M -$231.00 N/A Mymd Pharmaceuticals N/A N/A -$11.63M -$3.48 N/A

Is TNFA or QCLS more profitable?

TNF Pharmaceuticals' return on equity of -69.21% beat Mymd Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets TNF Pharmaceuticals N/A -69.21% -33.98% Mymd Pharmaceuticals N/A -91.64% -47.48%

Mymd Pharmaceuticals (QCLS) Competitors

$2.44 +0.03 (+1.24%)

Closing price 08/25/2026 04:00 PM Eastern

Extended Trading

$2.50 +0.06 (+2.42%)

As of 04:07 AM Eastern

Compare

QCLS vs. FOXX, EBON, AIMD, BOXL, and TNFA

Should you buy Mymd Pharmaceuticals stock or one of its competitors? Mymd Pharmaceuticals's main competitors and comparable companies include Foxx Development (FOXX), Ebang International (EBON), Ainos (AIMD), Boxlight (BOXL), and TNF Pharmaceuticals (TNFA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "technology hardware, storage & peripherals" industry.

How does Mymd Pharmaceuticals compare to Foxx Development?

Foxx Development (NASDAQ:FOXX) and Mymd Pharmaceuticals (NASDAQ:QCLS) are both small-cap technology companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, earnings, analyst recommendations, risk, valuation, dividends, media sentiment and institutional ownership.

In the previous week, Foxx Development and Foxx Development both had 1 articles in the media. Mymd Pharmaceuticals' average media sentiment score of 1.89 beat Foxx Development's score of 0.00 indicating that Mymd Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Foxx Development	Neutral
Mymd Pharmaceuticals	Very Positive

Foxx Development has a beta of -0.35, indicating that its stock price is 135% less volatile than the broader market. Comparatively, Mymd Pharmaceuticals has a beta of 2.16, indicating that its stock price is 116% more volatile than the broader market.

Foxx Development has higher revenue and earnings than Mymd Pharmaceuticals. Mymd Pharmaceuticals is trading at a lower price-to-earnings ratio than Foxx Development, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Foxx Development	$65.92M	0.31	-$9.02M	-$6.87	N/A
Mymd Pharmaceuticals	N/A	N/A	-$11.63M	-$3.48	N/A

60.4% of Foxx Development shares are held by institutional investors. Comparatively, 9.6% of Mymd Pharmaceuticals shares are held by institutional investors. 31.6% of Foxx Development shares are held by company insiders. Comparatively, 0.9% of Mymd Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Foxx Development	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Mymd Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Mymd Pharmaceuticals has a net margin of 0.00% compared to Foxx Development's net margin of -79.80%. Foxx Development's return on equity of 0.00% beat Mymd Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Foxx Development	-79.80%	N/A	-59.35%
Mymd Pharmaceuticals	N/A	-91.64%	-47.48%

Summary

Foxx Development beats Mymd Pharmaceuticals on 6 of the 11 factors compared between the two stocks.

How does Mymd Pharmaceuticals compare to Ebang International?

Ebang International (NASDAQ:EBON) and Mymd Pharmaceuticals (NASDAQ:QCLS) are both small-cap technology companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, earnings, profitability, media sentiment, valuation and risk.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ebang International	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Mymd Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Mymd Pharmaceuticals has lower revenue, but higher earnings than Ebang International.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ebang International	$6.54M	2.23	-$14.09M	N/A	N/A
Mymd Pharmaceuticals	N/A	N/A	-$11.63M	-$3.48	N/A

1.2% of Ebang International shares are held by institutional investors. Comparatively, 9.6% of Mymd Pharmaceuticals shares are held by institutional investors. 25.4% of Ebang International shares are held by insiders. Comparatively, 0.9% of Mymd Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Ebang International and Ebang International both had 1 articles in the media. Mymd Pharmaceuticals' average media sentiment score of 1.89 beat Ebang International's score of 0.00 indicating that Mymd Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Ebang International	Neutral
Mymd Pharmaceuticals	Very Positive

Ebang International's return on equity of 0.00% beat Mymd Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ebang International	N/A	N/A	N/A
Mymd Pharmaceuticals	N/A	-91.64%	-47.48%

Ebang International has a beta of 3, indicating that its share price is 200% more volatile than the broader market. Comparatively, Mymd Pharmaceuticals has a beta of 2.16, indicating that its share price is 116% more volatile than the broader market.

Summary

Ebang International beats Mymd Pharmaceuticals on 5 of the 8 factors compared between the two stocks.

How does Mymd Pharmaceuticals compare to Ainos?

Mymd Pharmaceuticals (NASDAQ:QCLS) and Ainos (NASDAQ:AIMD) are both small-cap technology companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, earnings, media sentiment, institutional ownership, analyst recommendations, profitability, dividends and risk.

9.6% of Mymd Pharmaceuticals shares are held by institutional investors. 0.9% of Mymd Pharmaceuticals shares are held by company insiders. Comparatively, 9.8% of Ainos shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Ainos had 1 more articles in the media than Mymd Pharmaceuticals. MarketBeat recorded 2 mentions for Ainos and 1 mentions for Mymd Pharmaceuticals. Mymd Pharmaceuticals' average media sentiment score of 1.89 beat Ainos' score of 0.40 indicating that Mymd Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Mymd Pharmaceuticals	Very Positive
Ainos	Neutral

Mymd Pharmaceuticals has a beta of 2.16, indicating that its stock price is 116% more volatile than the broader market. Comparatively, Ainos has a beta of 2.46, indicating that its stock price is 146% more volatile than the broader market.

Mymd Pharmaceuticals has a net margin of 0.00% compared to Ainos' net margin of -11,912.10%. Mymd Pharmaceuticals' return on equity of -91.64% beat Ainos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mymd Pharmaceuticals	N/A	-91.64%	-47.48%
Ainos	-11,912.10%	-217.50%	-67.87%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mymd Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Ainos	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Mymd Pharmaceuticals has higher earnings, but lower revenue than Ainos. Mymd Pharmaceuticals is trading at a lower price-to-earnings ratio than Ainos, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mymd Pharmaceuticals	N/A	N/A	-$11.63M	-$3.48	N/A
Ainos	$120K	89.18	-$14.77M	-$2.52	N/A

Summary

Mymd Pharmaceuticals and Ainos tied by winning 6 of the 12 factors compared between the two stocks.

How does Mymd Pharmaceuticals compare to Boxlight?

Mymd Pharmaceuticals (NASDAQ:QCLS) and Boxlight (NASDAQ:BOXL) are both small-cap technology companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, analyst recommendations, risk, profitability, institutional ownership and earnings.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mymd Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Boxlight	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Mymd Pharmaceuticals has a net margin of 0.00% compared to Boxlight's net margin of -20.96%. Boxlight's return on equity of 0.00% beat Mymd Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mymd Pharmaceuticals	N/A	-91.64%	-47.48%
Boxlight	-20.96%	N/A	-23.50%

Mymd Pharmaceuticals has higher earnings, but lower revenue than Boxlight. Mymd Pharmaceuticals is trading at a lower price-to-earnings ratio than Boxlight, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mymd Pharmaceuticals	N/A	N/A	-$11.63M	-$3.48	N/A
Boxlight	$109.25M	0.04	-$23.81M	-$80.86	N/A

Mymd Pharmaceuticals has a beta of 2.16, indicating that its share price is 116% more volatile than the broader market. Comparatively, Boxlight has a beta of 0.81, indicating that its share price is 19% less volatile than the broader market.

In the previous week, Boxlight had 2 more articles in the media than Mymd Pharmaceuticals. MarketBeat recorded 3 mentions for Boxlight and 1 mentions for Mymd Pharmaceuticals. Mymd Pharmaceuticals' average media sentiment score of 1.89 beat Boxlight's score of 0.00 indicating that Mymd Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Mymd Pharmaceuticals	Very Positive
Boxlight	Neutral

9.6% of Mymd Pharmaceuticals shares are owned by institutional investors. Comparatively, 6.5% of Boxlight shares are owned by institutional investors. 0.9% of Mymd Pharmaceuticals shares are owned by insiders. Comparatively, 15.4% of Boxlight shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Mymd Pharmaceuticals and Boxlight tied by winning 6 of the 12 factors compared between the two stocks.

How does Mymd Pharmaceuticals compare to TNF Pharmaceuticals?

TNF Pharmaceuticals (NASDAQ:TNFA) and Mymd Pharmaceuticals (NASDAQ:QCLS) are both small-cap technology companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, risk, earnings, profitability, valuation, dividends and institutional ownership.

TNF Pharmaceuticals' return on equity of -69.21% beat Mymd Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TNF Pharmaceuticals	N/A	-69.21%	-33.98%
Mymd Pharmaceuticals	N/A	-91.64%	-47.48%

Mymd Pharmaceuticals is trading at a lower price-to-earnings ratio than TNF Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TNF Pharmaceuticals	N/A	N/A	-$23.36M	-$231.00	N/A
Mymd Pharmaceuticals	N/A	N/A	-$11.63M	-$3.48	N/A

In the previous week, Mymd Pharmaceuticals had 1 more articles in the media than TNF Pharmaceuticals. MarketBeat recorded 1 mentions for Mymd Pharmaceuticals and 0 mentions for TNF Pharmaceuticals. Mymd Pharmaceuticals' average media sentiment score of 1.89 beat TNF Pharmaceuticals' score of 0.00 indicating that Mymd Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
TNF Pharmaceuticals	Neutral
Mymd Pharmaceuticals	Very Positive

9.6% of TNF Pharmaceuticals shares are owned by institutional investors. Comparatively, 9.6% of Mymd Pharmaceuticals shares are owned by institutional investors. 0.5% of TNF Pharmaceuticals shares are owned by insiders. Comparatively, 0.9% of Mymd Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

TNF Pharmaceuticals has a beta of 2.04, meaning that its stock price is 104% more volatile than the broader market. Comparatively, Mymd Pharmaceuticals has a beta of 2.16, meaning that its stock price is 116% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TNF Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Mymd Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Mymd Pharmaceuticals beats TNF Pharmaceuticals on 6 of the 10 factors compared between the two stocks.

Get Mymd Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding QCLS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

QCLS vs. The Competition

Export

Metric	Mymd Pharmaceuticals	Technology Hardware, Storage & Peripherals Industry	Technology Sector	NASDAQ Exchange
Market Cap	$19.74M	$112.76B	$28.90B	$12.72B
Dividend Yield	N/A	1.75%	2.75%	11.02%
P/E Ratio	-0.70	29.82	71.98	24.14
Price / Sales	N/A	90.21	593.88	101.63
Price / Cash	N/A	20.08	48.39	53.12
Price / Book	1.25	7.74	9.35	6.25
Net Income	-$11.63M	$3.57B	$676.63M	$347.86M
7 Day Performance	-9.29%	2.52%	0.73%	0.98%
1 Month Performance	-24.46%	8.12%	4.44%	5.24%
1 Year Performance	N/A	95.99%	188.19%	17.04%

Mymd Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
QCLS Mymd Pharmaceuticals	0.5745 of 5 stars	$2.44 +1.2%	N/A	N/A	$19.74M	N/A	N/A	6	Positive News
FOXX Foxx Development	0.2482 of 5 stars	$2.59 +0.4%	N/A	-56.3%	$18.17M	$65.92M	N/A	N/A	Gap Down
EBON Ebang International	0.4703 of 5 stars	$2.03 +3.6%	N/A	-40.8%	$12.83M	$6.54M	N/A	260	Gap Down
AIMD Ainos	0.6071 of 5 stars	$1.44 -3.4%	N/A	-62.2%	$11M	$120K	N/A	40	Gap Up
BOXL Boxlight	0.0887 of 5 stars	$6.80 -13.6%	N/A	-90.4%	$5.46M	$109.25M	N/A	180	Positive News Short Interest Increase Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:QCLS) was last updated on 8/26/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Mymd Pharmaceuticals (QCLS) Competitors

QCLS vs. FOXX, EBON, AIMD, BOXL, and TNFA

How does Mymd Pharmaceuticals compare to Foxx Development?

Summary

How does Mymd Pharmaceuticals compare to Ebang International?

Summary

How does Mymd Pharmaceuticals compare to Ainos?

Summary

How does Mymd Pharmaceuticals compare to Boxlight?

Summary

How does Mymd Pharmaceuticals compare to TNF Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

QCLS vs. The Competition

Mymd Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Mymd Pharmaceuticals (QCLS) Competitors

QCLS vs. FOXX, EBON, AIMD, BOXL, and TNFA

How does Mymd Pharmaceuticals compare to Foxx Development?

Does the media refer more to FOXX or QCLS?

Which has more volatility and risk, FOXX or QCLS?

Which has higher valuation and earnings, FOXX or QCLS?

Do institutionals & insiders have more ownership in FOXX or QCLS?

Do analysts rate FOXX or QCLS?

Is FOXX or QCLS more profitable?

Summary

How does Mymd Pharmaceuticals compare to Ebang International?

Do analysts prefer EBON or QCLS?

Which has stronger valuation & earnings, EBON or QCLS?

Do insiders & institutionals have more ownership in EBON or QCLS?

Does the media refer more to EBON or QCLS?

Is EBON or QCLS more profitable?

Which has more volatility & risk, EBON or QCLS?

Summary

How does Mymd Pharmaceuticals compare to Ainos?

Do institutionals and insiders believe in QCLS or AIMD?

Does the media prefer QCLS or AIMD?

Which has more volatility and risk, QCLS or AIMD?

Is QCLS or AIMD more profitable?

Do analysts prefer QCLS or AIMD?

Which has better earnings and valuation, QCLS or AIMD?

Summary

How does Mymd Pharmaceuticals compare to Boxlight?

Do analysts recommend QCLS or BOXL?

Is QCLS or BOXL more profitable?

Which has higher valuation and earnings, QCLS or BOXL?

Which has more volatility and risk, QCLS or BOXL?

Does the media prefer QCLS or BOXL?

Do institutionals and insiders hold more shares of QCLS or BOXL?

Summary

How does Mymd Pharmaceuticals compare to TNF Pharmaceuticals?

Is TNFA or QCLS more profitable?

Which has better earnings & valuation, TNFA or QCLS?

Does the media prefer TNFA or QCLS?

Do insiders & institutionals hold more shares of TNFA or QCLS?

Which has more volatility and risk, TNFA or QCLS?

Do analysts recommend TNFA or QCLS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

QCLS vs. The Competition

Mymd Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools